Fig. 4From: Effect of vitreomacular adhesion on the treatment outcomes in the STOP-Uveitis clinical trial for non-infectious uveitisStudy population. Flowchart outlining the characteristics of the study population. BCVA, best-corrected visual acuity; CRT, central retinal thickness; IV, intravenous; TCZ, tocilizumab; VH, vitreous haze; VMA+, vitreomacular adhesion present; VMA−, vitreomacular adhesion absent; Δ, mean change from baseline to month 6Back to article page